{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:12Z","timestamp":1791464232375,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104119","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:53:42Z","timestamp":1737215622000},"page":"104119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-3169","authenticated-orcid":false,"given":"M.","family":"Loverro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-3888","authenticated-orcid":false,"given":"L.","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-4193","authenticated-orcid":false,"given":"F.M.","family":"Capomacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Caricato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-5232","authenticated-orcid":false,"given":"M.","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Panico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9926-760X","authenticated-orcid":false,"given":"G.","family":"Avesani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cocciolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"A.","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.104119_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1016\/j.esmoop.2024.104119_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2024.104119_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Martin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104119_bib4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.104119_bib5","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.34350","article-title":"Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial)","volume":"128","author":"Marth","year":"2022","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2024.104119_bib6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.104119_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104119_bib8","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: real-world data from a multicenter study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Target Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104119_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104119_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104119_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104119_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"3-4","key":"10.1016\/j.esmoop.2024.104119_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A\u00a0treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.esmoop.2024.104119_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2024.104119_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","article-title":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","volume":"189","author":"Kamrava","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104119_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ijgc-2021-003053","article-title":"Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study","volume":"32","author":"Cerda","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104119_bib17","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A\u00a0large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104119_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaoncol.2024.1796","article-title":"Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogessive tumors","volume":"10","author":"Donovan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104119_bib19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104119_bib20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A\u00a0randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2024.104119_bib21","article-title":"Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: the CARACO phase III randomized trial","volume":"42","author":"Classe","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104119_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonzalez-Martin","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104119_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.104119_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104119_bib25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","volume":"31","author":"Monk","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"30","key":"10.1016\/j.esmoop.2024.104119_bib26","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104119_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.ejhg.5200755","article-title":"BRCA mutations in Italian breast\/ovarian cancer families","volume":"10","author":"Nedelcu","year":"2002","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104119_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ijgc-2024-005838","article-title":"A\u00a0randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067\/JGOG 3036\/APGOT-OV11)","volume":"34","author":"Cho","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104119_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.esmoop.2024.104119_bib30","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1016\/j.annonc.2024.08.2158","article-title":"798TiP Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial","volume":"35","author":"Banerjee","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:46:32Z","timestamp":1740141992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924018908"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104119","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104119"}}